1. Home
  2. OSRH vs INTS Comparison

OSRH vs INTS Comparison

Compare OSRH & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OSR Holdings Inc.

OSRH

OSR Holdings Inc.

N/A

Current Price

$0.51

Market Cap

18.4M

Sector

N/A

ML Signal

N/A

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

N/A

Current Price

$7.69

Market Cap

19.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OSRH
INTS
Founded
N/A
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.4M
19.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
OSRH
INTS
Price
$0.51
$7.69
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$56.25
AVG Volume (30 Days)
380.7K
757.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
15.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.38
$0.19
52 Week High
$4.33
$8.06

Technical Indicators

Market Signals
Indicator
OSRH
INTS
Relative Strength Index (RSI) 52.64 79.71
Support Level $0.45 $0.29
Resistance Level $0.74 $8.06
Average True Range (ATR) 0.05 0.52
MACD 0.02 -0.04
Stochastic Oscillator 62.57 83.73

Price Performance

Historical Comparison
OSRH
INTS

About OSRH OSR Holdings Inc.

OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Share on Social Networks: